New Alzheimer's drug passes first safety check in small study

NCT ID NCT05551741

First seen Nov 05, 2025 · Last updated May 07, 2026 · Updated 27 times

Summary

This early-stage study tested a new drug called IBC-Ab002 in 40 people with early Alzheimer's disease. The main goal was to see if the drug is safe and how the body processes it. Researchers gave increasing doses of the drug or a placebo to check for side effects and changes in lab tests, vital signs, and brain scans. This is a first step to see if the drug might help control symptoms in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Barzilai Medical Center

    Ashkelon, Israel

  • Brain Research Center

    Amsterdam, Netherlands

  • Dementia Research Centre, National Hospital for Neurology and Neurosurgery

    London, United Kingdom

  • King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN)

    London, SE5 8AF, United Kingdom

  • RICE - Research Institute for the Care of Older People

    Bath, BA1 3NG, United Kingdom

  • Rabin Medical Center

    Petah Tikva, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Sheffield teaching Hospitals NHS Trust

    London, United Kingdom

  • Tel-Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • University Hospital Southampton NHS Foundation Trust

    Southampton, Hampshire, United Kingdom

Conditions

Explore the condition pages connected to this study.